Biogen teams up with Columbia to decode ALS

Biogen ($BIIB) is joining Columbia University in an effort to sequence the genes of 1,500 people with amyotrophic lateral sclerosis, or ALS, hoping to better understand the disease's underlying biology to inform drug R&D. The idea is to spotlight the genetic roots of ALS, creating a database of patient data with the aid of a network of institutions. To fund the project, Biogen and Columbia will tap their $30 million research alliance and draw $3.5 million from the ALS Association, all of which was raised through last year's Ice Bucket Challenge. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.